Genetic Technologies Ltd. ADR (GENE) News
Filter GENE News Items
GENE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GENE News Highlights
- For GENE, its 30 day story count is now at 3.
- Over the past 14 days, the trend for GENE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about GENE are ASX, AFMD and AUS.
Latest GENE News From Around the Web
Below are the latest news stories about Genetic Technologies Ltd that investors may wish to consider to help them evaluate GENE as an investment opportunity.
Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.Diversified Genomics and AI driven preventative health company Genetic Technologies (GENE) announces the regulatory submission for its COVID-19 Serious Disease Risk Test, enabling the commercial release of the product within the United States.The commercial release is expected to occur before the end of May once the technical interface for the United States telehealth platform is... |
Company News for Apr 12, 2021Companies in the news are: AFMD, FUBO, GENE, CELC |
Genetic Technologies appoints Mike Tonroe as CFOMELBOURNE, Australia, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), announces the appointment of Michael Tonroe to the role of Chief Financial Officer, commencing on 28 June 2021. Michael has over 25 years’ experience in overseeing the finance function at both management and board-level positions for private and listed companies in Australia, UK, US and Canada. He also has extensive experience in the biotech space across both the financial and company secretary roles having most recently managed both functions for dual-listed Opthea Limited. Commenting on the appointment, Chairman, Peter Rubinstein said, “We are pleased to appoint Michael to the role of Chief Financial Officer. Michael’s background and ... |
Genetic Technologies Provides Update on COVID-19 Risk Test LaunchMELBOURNE, Australia, April 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business provides an update to the market on the progress of the US commercial availability of the Company’s COVID-19 Serious Disease Risk (“COVID-19 Risk Test”) via US Based Infinity BiologiX LLC (‘IBX’), (ref: ASX Announcement 3 March 2021). Genetic Technologies advises that the Company has completed all validation and data-based analysis for the COVID-19 Risk Test. IBX, our US based distribution partner is currently completing the technical interface with their telehealth partner for the commercial availability of the COVID-19 Risk Test across the United States. The technical interface is a requireme... |
Cannabis Stock Gainers And Losers From April 7, 2021GAINERS: Cannabics Pharmaceuticals (OTC: CNBX ) shares closed up 10.92% at $0.29 MGC Pharmaceuticals (OTC: MGCLF ) shares closed up 7.78% at $0.05 Psychemedics (NASDAQ: PMD ) shares closed up 3.9% at $6.92 Invictus MD Strategies (OTC: IVITF ) shares closed up 3.66% at $0.04 Alcanna (OTC: LQSIF ) shares closed up 3.54% at $6.21 Genetic Technologies (NASDAQ: GENE ) shares closed up 3.34% at $4.33 SOL Global Investments (OTC: SOLCF ) shares closed up 3.06% at $3.70 LOSERS: Zelira Therapeutics (OTC: ZLDAF ) shares closed down 11.11% at … Full story available on Benzinga.com |
Cannabis Stock Gainers And Losers From March 9, 2021GAINERS: ReneSola (NYSE: SOL ) shares closed up 36.68% at $13.60 Invictus MD Strategies (OTC: IVITF ) shares closed up 30% at $0.05 Hollister Biosciences (PINK: HSTRF ) shares closed up 23.19% at $0.34 MedMen Enterprises (OTCQX: MMNFF ) shares closed up 22.28% at $0.38 GrowGeneration (NASDAQ: GRWG ) shares closed up 18.07% at $44.62 MGC Pharmaceuticals (PINK: MGCLF ) shares closed up 17.36% at $0.05 Cannabix Technologies (PINK: BLOZF ) shares closed up 16.19% at $1.22 Curaleaf Holdings (OTCQX: CURLF ) shares closed up 15.93% at $16.37 Aphria (NASDAQ: APHA ) shares closed up 12.66% at $18.15 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 11.83% at $2.08 Greenlane Holdings (NASDAQ: GNLN ) shares closed up 11.38% at $5.58 Neptune Wellness Solns (NASDAQ: NEPT ) shares closed up 10.... |
Genetic Technologies Signs Multi-Year US Distribution Agreement for COVID Risk TestMELBOURNE, Australia, March 04, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI-driven preventative health business is pleased to announce a co-exclusive production and distribution rights and license agreement (‘Agreement’) with US-based Infinity BiologiX LLC (‘IBX’), a leading central laboratory providing sample collection and processing, storage, analytical services, and scientific and technical support, for the production, distribution and sale of the Company’s COVID-19 Serious Disease Risk (sdr) Test (‘COVID-19 Risk Test’) in the United States. Highlights Initial three-year co-exclusive licence agreement between IBX and GTG for the production, distribution, sales and marketing of GTG’s COVID-19 Risk Tes... |
Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report®MELBOURNE, Australia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced an interview with Dr. George Muchnicki, Chief Medical Officer and Executive Director, will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, February 27, at 7 p.m. local time in 73M homes across the United States. The RedChip Money Report® also airs on Bloomberg International in Europe in 100M homes at 6 pm local time on Sundays. In the exclusive interview, Dr. Muchnicki discusses the Company’s cancer predictive testing and assessment tools to help physicians proactively manage patient health. Also discussed is the global market opportunity, upcoming predictive te... |
Genetic Technologies Provides Update on COVID-19 Risk TestMolecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on the development of the Company’s COVID-19 Risk Test. Genetic Technologies has outlined additional findings in relation to its COVID-19 Risk Test. |
Genetic Technologies Provides Update on COVID-19 Disease Severity Test DevelopmentMELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) (“Genetic Technologies” or the "Company") is developing a Polygenic Risk Score (PRS) test for COVID-19 which may enable an assessment of risk of an individual developing a serious disease should they contract the virus. The test is intended to predict ‘disease severity’ using a combination of genetic and clinical information. The Company is pleased to provide the following update on the test development program: * Completed development of a prototype Polygenic Risk Score * Completed development of a clinical risk model * Completed evaluation of the combined (clinical + polygenic) comprehensive risk model * Sourced cross validation data (expec... |